18-MC reduces methamphetamine and nicotine self-administration in rats
18-MC reduces methamphetamine and nicotine self-administration in rats
复制标题
DOI：
10.1097/00001756-200006260-00041
复制
发表时间：
2000-06-26
期刊：
影响因子：
1.7
通讯作者：
Dickinson, HA
中科院分区：
文献类型：
--
作者：
Glick, SD;Maisonneuve, IM;Dickinson, HA
在以前的研究中，发现18-甲氧基冠孢定（18-MC），一种新的iboga生物碱同系物，减少吗啡和可卡因在大鼠静脉自给药。在本研究中，18-MC（1-40 mg/kg，i. p.）剂量依赖性地减少了甲基苯丙胺和尼古丁的静脉内自我给药。与之前的研究一样，在18-MC最高剂量给药后24 h以上，药物自我给药减少。18-MC与迄今为止研究的所有四种滥用药物的相互作用的比较表明，18-MC在减少甲基苯丙胺自我给药方面效果最差，在减少尼古丁自我给药方面效果最强。结果表明，烟碱拮抗作用的18-MC有助于其推定的抗成瘾疗效。NeuroReport 11：2013-2015（C）2000 Lippincott威廉姆斯& Wilkins.
In previous studies, 18-methoxycoronaridine (18-MC), a novel iboga alkaloid congener, has been found to decrease the intravenous self-administration of morphine and cocaine in rats. In the present study, 18-MC (1-40 mg/kg, i.p.) dose-dependently decreased the i.v. self-administration of methamphetamine and nicotine. As in the previous studies, drug self-administration was reduced for greater than or equal to 24 h after the highest dose of 18-MC. A comparison of 18-MC's interactions with all four drugs of abuse studied so far indicated that 18-MC is least effective in decreasing methamphetamine self-administration and most potent in decreasing nicotine self-administration. The results suggest that a nicotinic antagonist action of 18-MC contributes to its putative anti-addictive efficacy. NeuroReport 11:2013-2015 (C) 2000 Lippincott Williams & Wilkins.